Synthekine Overview

  • Founded
  • 2018
Founded
  • Status
  • Private
  • Employees
  • 65
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $108M
Latest Deal Amount
  • Investors
  • 12

Synthekine General Information

Description

Developer of engineered cytokine therapeutics designed to facilitate disease-optimized treatments. The company leverages immunological insights to guide targeted protein engineering and generate transformative medicines, enabling the medical community to optimize the treatment of cancer and autoimmune disorders.

Contact Information

Website
www.synthekine.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 1505 O'Brien Drive
  • Suite A1
  • Menlo Park, CA 94025
  • United States
+1 (650) 000-0000

Synthekine Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Synthekine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 10-Jun-2021 $108M 00000 00000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 17-Sep-2020 000.00 000.00 00000 Completed Pre-Clinical Trials
To view Synthekine’s complete valuation and funding history, request access »

Synthekine Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 41,111,110 $0.000010 8% $1 $1 1x $1 28.24%
To view Synthekine’s complete cap table history, request access »

Synthekine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of engineered cytokine therapeutics designed to facilitate disease-optimized treatments. The company leverages
Drug Discovery
Menlo Park, CA
65 As of 2022
00000
0000 0000-00-00
00000000000 00000

00000000

iam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute ir
0000 000000000
Pittsburgh, PA
00 As of 0000
0000
000000 0 0000

000000 0

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore
0000 00000000
Irvine, CA
00 As of 0000
000.00
0000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Synthekine Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytoAgents Venture Capital-Backed Pittsburgh, PA 00 0000 000000 0 0000
000000 00000000000 Formerly VC-backed Irvine, CA 00 000.00 000000&0
0000000 0000000 Corporate Backed or Acquired Pennington, NJ 00 0000 00000000 0000
You’re viewing 3 of 3 competitors. Get the full list »

Synthekine Patents

  • 2

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Synthekine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210275641-A1 Biased il2 muteins methods and compositions Pending 14-Jan-2020 00000000000
US-20210196796-A1 Il-2 orthologs and methods of use Pending 13-Dec-2019 000000000

Synthekine Executive Team (6)

Name Title Board Seat Contact Info
Debanjan Ray President & Chief Executive Officer
Martin Oft MD Chief Development Officer
Robin Knifsend Senior Vice President, Finance & Operations
Naiyer Rizvi MD Chief Medical Officer
Christopher Garcia Ph.D Scientific Founder
You’re viewing 5 of 6 executive team members. Get the full list »

Synthekine Board Members (6)

Name Representing Role Since
Julie Grant Canaan Partners Board Member 000 0000
Mardi Dier Self Board Member 000 0000
Nils Lonberg Ph.D Canaan Partners Board Member 000 0000
Pablo Cagnoni Ph.D Self Board Member 000 0000
Srinivas Akkaraju Ph.D Samsara BioCapital Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Synthekine Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synthekine Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bain Capital Life Sciences Corporate Venture Capital Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Janus Henderson Investors Asset Manager Minority 000 0000 000000 0
Lilly Asia Ventures Venture Capital Minority 000 0000 000000 0
Omega Funds PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial